Kyntra Bio (NASDAQ:KYNB) Upgraded at Wall Street Zen

Kyntra Bio (NASDAQ:KYNB) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

KYNB has been the subject of a number of other research reports. HC Wainwright raised shares of Kyntra Bio to a “strong-buy” rating in a research report on Friday, February 27th. Zacks Research downgraded shares of Kyntra Bio from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Finally, Weiss Ratings initiated coverage on shares of Kyntra Bio in a research report on Wednesday, January 14th. They issued a “sell (d+)” rating for the company. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold”.

Kyntra Bio Trading Up 1.8%

Shares of NASDAQ:KYNB opened at $7.32 on Friday. Kyntra Bio has a fifty-two week low of $4.85 and a fifty-two week high of $12.60. The firm’s 50-day simple moving average is $7.19. The company has a market cap of $29.65 million, a P/E ratio of 0.16 and a beta of 0.90.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.